Hematologic Malignancy
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CI-CAN-00008233Explore in graph →
Hematologic72 active trials2 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008233Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (41)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 12, 2024source: clinicaltrials